Epilepsy and paroxysmal conditions

Advanced search

The role of glutamine synthetase expression and cystine/glutamate transporter (SLC7A11, xCT) in epilepsy pathogenesis of patients with supratentorial brain gliomas


Background. Epileptic seizures represent one of the leading clinical manifestations of glial brain tumors that develop on average in 51% of cases. In gliomas, epileptogenesis is quite complex and multifactorial.

Objective: to study a role of the expressed glutamine synthetase enzyme, as well as cystine/glutamate transporter (xCT system, SLC7A11) in the pathogenesis of epilepsy developing in patients with cerebral gliomas.

Material and methods. The study included 32 patients with supratentorial gliomas. The average age of the disease onset (diagnosis) was 50.69±18.01 years. All patients underwent inpatient examination and treatment at the Neurosurgery and Nervous Diseases Clinics of Kirov Military Medical Academy from 2018 to 2020. In all cases, a biopsy of tumor tissue was collected. Histological and immunohistochemical studies were performed (expression of glutamine synthetase and cystine/ glutamate transporter (SLC7A11, xCT)).

Results. Significant (ANOVA p=0.027, Mann–Whitney U-test p=0.033) differences in the expression of cystine/glutamate transporter (xCT system, SLC7A11) were revealed, by showing the following median values (lower quartile; upper quartile): 50% (45; 75) in the group of patients with seizures, 40% (40; 50) in the seizure-free group. The expression level of glutamine synthetase did not significantly differ in the groups with and without seizures.

Conclusion. The data obtained confirmed that one of the pathogenetic mechanisms for epilepsy development in patients with gliomas was related to highly expressed cystine/glutamate transporter (xCT system, SLC7A11) and, as a consequence, an increase in the extracellular glutamate level.

About the Authors

M. Yu. Prokudin
Kirov Military Medical Academy
Russian Federation

Mikhail Yu. Prokudin – MD, PhD, Faculty Member, Chair of Nervous Diseases

Saint Petersburg, Russia

RSCI SPIN-code: 4021-4432

B. V. Martynov
Kirov Military Medical Academy
Russian Federation

Boris V. Martynov – Dr. Med. Sc., Associate Professor, Neurosurgeon

Saint Petersburg

RSCI SPIN-code: 9953-3997

A. I. Yakovenko
Kirov Military Medical Academy
Russian Federation

Andrey I. Yakovenko – MD, PhD, Head of Pathomorphological Department, Central Pathology Laboratory

Saint Petersburg

RSCI SPIN-code: 5937-8120.

I. V. Litvinenko
Kirov Military Medical Academy
Russian Federation

Igor V. Litvinenko – Dr. Med. Sc., Professor, Head of Chair of Nervous Diseases

Saint Petersburg

WoS ResearcherID: F-9120-2013;

Scopus Author ID: 35734354000;

RSCI SPIN-code: 6112-2792.

V. Yu. Lobzin
Kirov Military Medical Academy; Mechnikov North-Western State Medical University; Children's Research and Clinical Center for Infectious Diseases, FMBA of Russia
Russian Federation

Vladimir Yu. Lobzin – Dr. Med. Sc., Professor, Chair of Nervous Diseases; Professor, Chair of Neurology; Senior Researcher, Research Department of Neuroinfections and Organic Pathology of the Nervous System

Saint Petersburg

WoS ResearcherID: I-4819-2016;

Scopus Author ID: 57203881632;

RSCI SPIN-code: 7779-3569.

D. V. Svistov
Kirov Military Medical Academy;
Russian Federation

Dmitriy V. Svistov – MD, PhD, Associate Professor, Head of Chair of Neurosurgery; Chief Neurosurgeon of the Ministry of Defense of the Russian Federation

Saint Petersburg

RSCI SPIN-code: 3184-5590.

V. S. Chirskiy
Kirov Military Medical Academy
Russian Federation

Vadim S. Chirskiy – Dr. Med. Sc., Head of Chair of Pathological Anatomy; Head of Department, Central Pathology Laboratory of the Ministry of Defense of the Russian Federation

Saint Petersburg

Moscow, Russia

RSCI SPIN-code: 7295-3369.

K. A. Chemodakova
Kirov Military Medical Academy
Russian Federation

Ksenia A. Chemodakova – Neurosurgeon, Neurosurgery Clinic

Saint Petersburg

RSCI SPIN-code: 8425-1808.

O. А. Klitsenko
Mechnikov North-Western State Medical University
Russian Federation

Olga A. Klitsenko – PhD (Biol.), Associate Professor, Chair of Pedagogy, Philosophy and Law

Saint Petersburg

RSCI SPIN-code: 7354-3080.



1. Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 (6): 394–424.

2. Ostrom Q.T., Cioffi G., Gittleman H., et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 2019; 21 (Suppl. 5): v1–100.

3. Prokudin M.Yu., Odinak M.M., Litvinenko I.V., et al. Clinical and morphological risk factors for epilepsy in patients with glial and metastatic brain tumors. S.S. Korsakov Journal of Neurology and Psychiatry. 2020; 120 (11): 22–8 (in Russ.).

4. Liubinas S.V., O’Brien T.J., Moffat B.M., et al. Tumour associated epilepsy and glutamate excitotoxicity in patients with gliomas. J Clin Neurosci. 2014; 21 (6): 899–908.

5. Buckingham S.C., Campbell S.L, Haas B.R., et al. Glutamate release by primary brain tumors induces epileptic activity. Nat Med. 2011; 17 (10): 1269–74.

6. Toledo M., Sarria-Estrada S., Quintana M., et al. Prognostic implications of epilepsy in glioblastomas. Clin Neurol Neurosurg. 2015; 139: 166–71.

7. Litvinenko I.V., Vorob’ev S.V., Lobzin V.Iu., Lupanov I.A. Possibilities of pharmacological modulation of brain glutamatergic system in the treatment of vascular cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2013; 113 (9): 29–35 (in Russ.).

8. Litvinenko I.V., Krasakov I.V., Bisaga G.N., et al. Modern conception of the pathogenesis of neurodegenerative diseases and therapeutic strategy. S.S. Korsakov Journal of Neurology and Psychiatry. 2013; 117 (6-2): 3–10 (in Russ.).

9. Rosati A., Poliani P.L., Todeschini A., et al. Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro Oncol. 2013; 15 (5): 618–25.

10. Rosati A., Marconi S., Pollo B., et al. Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels. J Neurooncol. 2009; 93 (3): 319–24.

11. Sørensen M.F., Heimisdόttir S.B., Sørensen M.D., et al. High expression of cystin-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma. J Neurooncol. 2018; 138 (1): 49–53.

12. Robert S.M., Buckingham S.C., Campbell S.L., et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Sci Transl Med. 2015; 7 (289): 289ra86.

13. Behrens P.F., Langemann H., Strohschein R., et al. Extracellular glutamate and other metabolites in and around RG2 rat glioma: an intracerebral microdialysis study. J Neurooncol. 2000; 47 (1): 11–22.

14. Neal A., Moffat B.A., Stein J.M., et al. Glutamate weighted imaging contrast in gliomas with 7 Tesla magnetic resonance imaging. Neuroimage Clin. 2019; 22: 101694.

15. Kempski O., Staub F., Jansen M., Baethmann A. Molecular mechanisms of glial cell swelling in acidosis. Adv Neurol. 1990; 52: 39–45.

16. Beaumont A., Whittle I.R. The pathogenesis of tumour associated epilepsy. Acta Neurochir (Wien). 2000; 142 (1): 1–15.

17. Patt S., Steenbeck J., Hochstetter A., et al. Source localization and possible causes of interictal epileptic activity in tumor-associated epilepsy. Neurobiol Dis. 2000; 7 (4): 260–9.


For citations:

Prokudin M.Yu., Martynov B.V., Yakovenko A.I., Litvinenko I.V., Lobzin V.Yu., Svistov D.V., Chirskiy V.S., Chemodakova K.A., Klitsenko O.А. The role of glutamine synthetase expression and cystine/glutamate transporter (SLC7A11, xCT) in epilepsy pathogenesis of patients with supratentorial brain gliomas. Epilepsy and paroxysmal conditions. 2022;14(2):204-213. (In Russ.)

Views: 656

ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)